TMCnet News
Research and Markets: Gene Therapy - Technologies, Markets and Companies - 2014-2023DUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/bnbkft/gene_therapy) has announced the addition of Jain PharmaBiotech's new report "Gene Therapy - Technologies, Markets and Companies" to their offering. Since the death of Jesse Gelsinger in the US following a gene therapy treatment, the FDA has further tightened the regulatory control on gene therapy. A further setback was the reports of leukemia following use of retroviral vectors in successful gene therapy for adenosine deaminase deficiency. Several clinical trials were put on hold and many have resumed now. The report also discusses the adverse effects of various vectors, safety regulations and ethical aspects of gene therapy including germline gene therapy. The markets for gene therapy are difficult to estimate as there is only one approved gene therapy product and it is marketed in China since 2004. Gene therapy markets are estimated for the years 2013-2023. The estimates are based on epidemiology of diseases to be treated wth gene therapy, the portion of those who will be eligible for these treatments, competing technologies and the technical developments anticipated in the next decades. In spite of some setbacks, the future for gene therapy is bright. The markets for DNA vaccines are calculated separately as only genetically modified vaccines and those using viral vectors are included in the gene therapy markets The voluminous literature on gene therapy was reviewed and selected 750 references are appended in the bibliography. The references are constantly updated. The text is supplemented with 74 tables and 15 figures. Profiles of 179 companies involved in developing gene therapy are presented along with 221 collaborations. There were only 44 companies involved in this area in 1995. In spite of some failures and mergers, the number of companies has increased more than 4-fold within a decade. These companies have been followed up since they were the topic of a book on gene therapy companies by the author of this report. John Wiley & Sons published the book in 2000 and from 2001 to 2003, updated versions of these companies (approximately 160 at mid-2003) were available on Wiley's web site. Since that free service was discontinued and the rights reverted to the author, this report remains the only authorized continuously updated version on gene therapy companies. Benefits of this report - Up-to-date on-stop information on gene therapy with 73 tables and 15 figures - Evaluation of gene therapy technologies - 750 selected references from the literature - Estimates of gene therapy markets from 2013-2023 - Profiles of 179 companies involved and collaborations in this area Who should read this report? - Biotechnology companies developing gene therapy - Academic institutions doing research in gene therapy - Drug delivery companies - Pharmaceutical companies interested in gene therapy - Gene therapy companies - Venture capital and investment companies For more information visit http://www.researchandmarkets.com/research/bnbkft/gene_therapy Source (News - Alert): Jain PharmaBiotech |
